0 Комментарии
0 Поделились
156 Просмотры
0 предпросмотр
Поиск
Знакомьтесь и заводите новых друзей
-
Новости
- ИССЛЕДОВАТЬ
-
Страницы
-
Группы
-
Мероприятия
-
Reels
-
Статьи пользователей
-
Маркет
-
Offers
-
Jobs
-
Войдите, чтобы отмечать, делиться и комментировать!
-
The Evolving Arsenal: How Oncology Chemotherapy Drugs Are Being Augmented by Targeted and Epigenetic TherapiesThe landscape of cancer treatment has undergone a dramatic transformation, moving beyond traditional chemotherapy to include a diverse range of targeted and biologic therapies. Oncology chemotherapy drugs now encompass a broad spectrum of agents, from cytotoxic chemotherapies to targeted small molecules, immunotherapies, and epigenetic therapies like decitabine. The global...0 Комментарии 0 Поделились 417 Просмотры 0 предпросмотр
-
Epidermal Growth Factor Receptor Inhibitor Market Growth Drivers and Investment OpportunitiesThe global Epidermal Growth Factor Receptor (EGFR) inhibitor industry is witnessing substantial momentum due to the increasing prevalence of cancer, growing adoption of targeted therapies, and advancements in precision medicine. The Epidermal Growth Factor Receptor Inhibitor Market size is expected to reach US$ 32.14 Billion by 2034 from US$ 15.92 Billion in 2025. The market is estimated to...0 Комментарии 0 Поделились 1Кб Просмотры 0 предпросмотр
-
Global Post-CDK4/6 Treatment Line Oncology Drugs Market Report: Precision Oncology, Treatment Innovation and Growth ProspectsAccording to the latest report published by Data Bridge Market Research, the Post-CDK4/6 Treatment Line Oncology Drugs Market CAGR Value The global post-CDK4/6 treatment line oncology drugs market size was valued at USD 3.53 billion in 2025 and is expected to reach USD 10.06 billion by 2033, at a CAGR of 14.00% during the forecast period The...0 Комментарии 0 Поделились 69 Просмотры 0 предпросмотр
-
Lymphoma Treatment Market Growth Potential Driven by Advances in Cancer TherapeuticsThe lymphoma treatment market is witnessing significant growth as healthcare providers increasingly focus on improving outcomes for patients diagnosed with Hodgkin lymphoma and non-Hodgkin lymphoma. Rising cancer prevalence, advancements in oncology research, and the growing adoption of innovative treatment approaches are contributing to the expansion of the market. The development of targeted...0 Комментарии 0 Поделились 1Кб Просмотры 0 предпросмотр